Analysts predict that Accuray Incorporated (NASDAQ:ARAY) will announce earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Accuray’s earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.09). Accuray reported earnings per share of ($0.12) in the same quarter last year, which suggests a positive year over year growth rate of 41.7%. The company is scheduled to issue its next quarterly earnings results on Thursday, October 26th.
According to Zacks, analysts expect that Accuray will report full year earnings of ($0.15) per share for the current financial year, with EPS estimates ranging from ($0.19) to ($0.13). For the next fiscal year, analysts forecast that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.08) to ($0.03). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Accuray.
Accuray (NASDAQ:ARAY) last released its earnings results on Tuesday, August 22nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.05). The firm had revenue of $112.09 million during the quarter, compared to analyst estimates of $112.00 million. Accuray had a negative net margin of 7.71% and a negative return on equity of 61.62%. The business’s revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.09) earnings per share.
A number of research firms have recently issued reports on ARAY. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 target price on shares of Accuray in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated a “hold” rating and issued a $5.00 target price on shares of Accuray in a research note on Thursday, August 24th. BTIG Research reiterated a “hold” rating on shares of Accuray in a research note on Thursday, August 24th. Zacks Investment Research upgraded Accuray from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, BidaskClub lowered Accuray from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $5.85.
Several hedge funds have recently bought and sold shares of ARAY. Neuberger Berman Group LLC grew its stake in shares of Accuray by 26.7% in the first quarter. Neuberger Berman Group LLC now owns 5,014,941 shares of the medical equipment provider’s stock valued at $23,821,000 after buying an additional 1,057,654 shares in the last quarter. Vident Investment Advisory LLC grew its stake in shares of Accuray by 212.7% in the first quarter. Vident Investment Advisory LLC now owns 1,553,111 shares of the medical equipment provider’s stock valued at $7,377,000 after buying an additional 1,056,395 shares in the last quarter. Bogle Investment Management L P DE acquired a new stake in shares of Accuray in the first quarter valued at about $1,952,000. Vanguard Group Inc. grew its stake in shares of Accuray by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,447,130 shares of the medical equipment provider’s stock valued at $30,623,000 after buying an additional 286,011 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Accuray by 31.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,124,803 shares of the medical equipment provider’s stock valued at $5,343,000 after buying an additional 266,790 shares in the last quarter. Institutional investors and hedge funds own 76.67% of the company’s stock.
Accuray (NASDAQ ARAY) traded down 3.26% during trading on Friday, reaching $4.45. The company’s stock had a trading volume of 247,597 shares. The company’s market capitalization is $370.15 million. The company’s 50-day moving average is $4.15 and its 200-day moving average is $4.43. Accuray has a 1-year low of $3.60 and a 1-year high of $6.39.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/21/zacks-brokerages-anticipate-accuray-incorporated-aray-will-post-earnings-of-0-07-per-share.html.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.